Immunis, Inc.

Immunis, Inc. is a private biotechnology company founded in 2018 and based in the United States. The company's slogan, "Developing immunomodulatory secretomes for age and immune-related diseases," succinctly captures its focus on addressing age-related and disease-related immune deficits. Immunis has distinguished itself through the development of a novel method for growing human cells for clinical use, directing them to become highly pure populations of defined cells that secrete factors benefiting immune system development, modulation, and health. The last investment in Immunis, Inc. was a significant $10.00M Series A investment on 03 August 2022, led by Remiges Ventures and Continuum Health Ventures. This infusion of funding underscores investor confidence in the potential of Immunis' proprietary technology and investigational product. Immunis' first clinical trial, a Phase 1/2a study, focuses on evaluating the effectiveness of STEM in treating muscle atrophy, a common age-related condition. This trial marks a pivotal step in demonstrating the practical application of Immunis' technology and its potential to address prevalent health challenges associated with aging. The company's commitment to leveraging all-natural, all-human investigational products, which represent a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations, positions Immunis at the forefront of biotechnological innovation. As the company continues to advance its pioneering approach, it has the potential to make significant strides in enhancing immune system health and combating age-related and immune-related diseases.